Source: Geron Corporation
Date: August 27, 2007
Summary:
In an official company news release, Geron Corporation reported its scientists and collaborators have demonstrated that human embryonic stem cell (hESC)-derived cardiomyocytes (heart cells) improve heart function when transplanted after myocardial infarction. Published online Aug. 26 in Nature Biotechnology, the landmark study is the first to document the potential clinical utility of regenerating damaged heart muscle by injecting hESC-derived cardiomyocytes directly into the site of the infarct. In addition, the research confirms the effectiveness of a scalable production system that enables Geron to manufacture the cardiomyocytes for use in ongoing large animal studies and, ultimately, testing in humans.
